Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Waltz

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Science (New York, N.Y.)|April 4, 2009
Computer science. Automating scienceDavid Waltz, Bruce G Buchanan
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 30, 2016
Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapyGautham Marigowda, Fang Liu, David Waltz
American Journal of Respiratory and Critical Care Medicine|November 3, 2016
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTRCarlos E Milla, Felix Ratjen, Gautham Marigowda, et al.
The Lancet. Respiratory Medicine|June 15, 2016
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisJ Stuart Elborn, Bonnie W Ramsey, Michael P Boyle, et al.
Lancet (London, England)|August 31, 2020
Transparency and diversity in cystic fibrosis research - Authors' replyKaren S McCoy, Harry Heijerman, Jennifer L Taylor-Cousar, et al.
Annals of the American Thoracic Society|November 30, 2016
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTRSteven M Rowe, Susanna A McColley, Ernst Rietschel, et al.
The Lancet. Respiratory Medicine|June 14, 2017
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trialFelix Ratjen, Christopher Hug, Gautham Marigowda, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 12, 2017
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTRJennifer L Taylor-Cousar, Manu Jain, Tara Lynn Barto, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 27, 2018
Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosisAaron T Trimble, A Whitney Brown, Beth L Laube, et al.
The Lancet. Respiratory Medicine|June 29, 2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael P Boyle, Scott C Bell, Michael W Konstan, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Science (New York, N.Y.)|April 4, 2009
Computer science. Automating scienceDavid Waltz, Bruce G Buchanan
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 30, 2016
Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapyGautham Marigowda, Fang Liu, David Waltz
American Journal of Respiratory and Critical Care Medicine|November 3, 2016
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTRCarlos E Milla, Felix Ratjen, Gautham Marigowda, et al.
The Lancet. Respiratory Medicine|June 15, 2016
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisJ Stuart Elborn, Bonnie W Ramsey, Michael P Boyle, et al.
Lancet (London, England)|August 31, 2020
Transparency and diversity in cystic fibrosis research - Authors' replyKaren S McCoy, Harry Heijerman, Jennifer L Taylor-Cousar, et al.
Annals of the American Thoracic Society|November 30, 2016
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTRSteven M Rowe, Susanna A McColley, Ernst Rietschel, et al.
The Lancet. Respiratory Medicine|June 14, 2017
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trialFelix Ratjen, Christopher Hug, Gautham Marigowda, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 12, 2017
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTRJennifer L Taylor-Cousar, Manu Jain, Tara Lynn Barto, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 27, 2018
Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosisAaron T Trimble, A Whitney Brown, Beth L Laube, et al.
The Lancet. Respiratory Medicine|June 29, 2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael P Boyle, Scott C Bell, Michael W Konstan, et al.
Pageof 4